Find the latest argenx SE (ARGX.BR) stock quote, history, news and other vital information to help you with your stock trading and investing.

argenx SE (ARGX) is up 6.1% today. Here is some analysis on what might have caused this price moveme

ALKIVIA beat placebo by 15.40 points at 52 weeks. Argenx stock costs EUR 769.30 on October 20, 2026,

The Dutch biotechnology company rebounds sharply during the session, after a lackluster low and two days ahead of a quarterly meeting. A price target increase signed by a French brokerage firm accompanies this renewed appetite, in a Paris market that is declining.

argenx SE ADR (ARGX) has an average rating of buy and mean price target of $1,162.98, according to a

Argenx announced on October 19, 2026, the forthcoming presentation of results from the phase 3 ALKIVIA study in autoimmune myositis, whose primary endpoint was met with a difference of 15.4 points in favor of efgartigimod on the Total Improvement Score (TIS) at 52 weeks. This result applies to the combined population of patients with immune-mediated necrotizing myopathy (IMNM) and dermatomyositis (DM). According to the group, therapeutic options are limited in these two forms, and there is no approved treatment in IMNM.<br><br>This publication comes shortly after the discontinuation, announced on October 8, 2026, of the phase 3 UNITY trial of the same molecule in Sjögren's disease, on the recommendation of an independent data monitoring committee which determined that the study would not be able to achieve its primary endpoint. ALKIVIA, presented by Argenx as the first registration study of an FcRn blocker in autoimmune myositis, will be detailed on November 11, 2026 at the ACR Conv…

Encuentre las cotizaciones de acciones, el historial, las noticias y otra información vital más reciente de argenx SE (ARGX) para ayudarle con su negociación e inversión en acciones.